DESyne novolimus-eluting coronary stent is superior to Endeavor zotarolimus-eluting coronary stent at five-year follow-up: final results of the multicentre EXCELLA II randomised controlled trial
EuroIntervention
; 11(6): 20150130-20150131, 2015.
Artigo
em Inglês
| Sec. Est. Saúde SP, SESSP-IDPCPROD, Sec. Est. Saúde SP
| ID: biblio-1062695
Biblioteca responsável:
BR79.1
Localização: BR79.1
ABSTRACT
Aims:
Newer-generation drug-eluting stents (DES) have been shown to be superior to first-generation DES. Current-generation DES have zotarolimus, everolimus or biolimus as antiproliferative drugs. Novolimus, a metabolite of sirolimus, has been specifically developed to provide efficacy similar to currently available agents at a lower dose and thus requires a lower polymer load. We report the final five-year outcomes of the EXCELLA II trial comparing a zotarolimus-eluting stent (ZES) with a novolimus-eluting stent (NES).Methods andresults:
EXCELLA II is a prospective, multicentre, single-blind, non-inferiority clinical trial. Patients (n=210) with a maximum of two de novo lesions in two different epicardial vessels were randomised (21) to treatment with either NES (n=139) or ZES (n=71). At five-year follow-up, patients in the NES group had a significantly lower incidence of the patient-oriented (HR 0.53, 95% CI 0.32-0.87, p=0.013) and device-oriented (HR 0.38, 95% CI 0.17-0.83, p=0.011) composite endpoints. There was no difference in cardiac death and definite/probable stent thrombosis between the two groups; however, there was a trend towards reduction in myocardial infarction and repeat revascularisation in the NES group at five-year follow-up.Conclusions:
At five-year follow-up, the incidence of device- and patient-oriented events was significantly lower in the NES group. Further studies, adequately powered for clinical outcomes, are warranted. Trial Registration ClinicalTrials.gov number NCT00792753.
Buscar no Google
Coleções:
Bases de dados nacionais
/
Brasil
Base de dados:
Sec. Est. Saúde SP
/
SESSP-IDPCPROD
Assunto principal:
Stents Farmacológicos
/
Everolimo
Tipo de estudo:
Ensaio clínico controlado
Idioma:
Inglês
Revista:
EuroIntervention
Ano de publicação:
2015
Tipo de documento:
Artigo
Instituição/País de afiliação:
Academisch Ziekenhuis Middelheim/BE
/
Auckland City Hospital/NZ
/
Bern University Hospital/CH
/
Cardialysis BV/NL
/
Elixir Medical Corp/US
/
Instituto Dante Pazzanese de Cardiologia/BR
/
Stanford University/US
/
Thoraxcenter, Erasmus MC/NL